PUBLISHER: Bizwit Research & Consulting LLP | PRODUCT CODE: 1579943
PUBLISHER: Bizwit Research & Consulting LLP | PRODUCT CODE: 1579943
Global Keratoconjunctivitis Market Size study, by Drug Class, by Route of Administration, by End-Users, by Distribution Channel and Regional Forecasts 2022-2032
Global Keratoconjunctivitis Market is valued at approximately USD 472.46 Million in 2023 and is anticipated to grow with a healthy growth rate of more than 5.31% over the forecast period 2024-2032. Keratoconjunctivitis is an inflammatory condition that affects both the cornea and conjunctiva, typically arising from infections, allergies, or environmental irritants. It encompasses various forms, such as viral, bacterial, allergic, and dry eye-related keratoconjunctivitis. Common symptoms include redness, itching, and discharge, indicative of the inflammation impacting the eye's surface. The increasing prevalence of allergies and environmental factors, particularly in urbanized regions, is fueling the growth of the keratoconjunctivitis market. Additionally, technological advancements in biotechnology, such as high-resolution ocular surface imaging and tear break-up time analyzers, have significantly enhanced diagnostic accuracy, contributing to improved treatment outcomes. These advancements are key drivers of the market's growth, as they improve patient care and support the rising demand for effective keratoconjunctivitis treatments.
The Global Keratoconjunctivitis Market is poised for significant growth, driven by the increasing availability of treatments through retail pharmacies and the expansion of these outlets in developed regions. Retail pharmacies are responding to the growing demand for accessible and convenient healthcare solutions by offering a wider range of over-the-counter and prescription treatments for keratoconjunctivitis. This development not only enhances patient adherence to prescribed treatments but also opens up substantial market opportunities. However, the market faces challenges such as the rising incidence of antibiotic-resistant bacterial strains due to the overuse of antibiotics, which complicates treatment and drives up healthcare costs. Moreover, a shortage of skilled ophthalmologists, especially in regions like sub-Saharan Africa, limits the effective use of advanced diagnostic tools and therapies, constraining market growth.
The key regions considered for the Global Keratoconjunctivitis Market study include Asia Pacific, North America, Europe, Latin America, Middle East & Africa, and Rest of the World. North America is a dominating region in the Global Keratoconjunctivitis Market in terms of revenue. The market growth in the region is being attributed to factors including strong demand for innovative therapies, a large patient population, and favorable reimbursement policies. The presence of key market players further strengthens the region's market position. Whereas, the market in Asia Pacific is anticipated to grow at the fastest rate over the forecast period fueled by increasing awareness of keratoconjunctivitis, expanding healthcare infrastructure, and a rising prevalence of the condition in densely populated countries such as China and India.
Major market players included in this report are:
- Bausch Health Companies Inc. (U.S.)
- Merck & Co. Inc. (U.S.)
- Pfizer Inc. (U.S.)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Amorphex Therapeutics Holdings, Inc (U.S.)
- Bayer AG (Germany)
- Novartis AG (Switzerland)
- Dr. Reddy's Laboratories Ltd (India)
- Endo International plc (Ireland)
- Lupin (India)
The detailed segments and sub-segment of the market are explained below:
By Drug Class
- NSAIDs
- Corticosteroids
- Antibiotics
- Antivirals
- Others
By Route of Administration
- Oral
- Topical
- Others
By End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
By Region:
- North America
- U.S.
- Canada
- Europe
- UK
- Germany
- France
- Spain
- Italy
- ROE
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- RoAPAC
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- Saudi Arabia
- South Africa
- RoMEA
Years considered for the study are as follows:
- Historical year - 2022
- Base year - 2023
- Forecast period - 2024 to 2032
Key Takeaways:
- Market Estimates & Forecast for 10 years from 2022 to 2032.
- Annualized revenues and regional-level analysis for each market segment.
- Detailed analysis of geographical landscape with Country level analysis of major regions.
- Competitive landscape with information on major players in the market.
- Analysis of key business strategies and recommendations on future market approach.
- Analysis of the competitive structure of the market.
Table of Contents
Chapter 1. Global Keratoconjunctivitis Market Executive Summary
- 1.1. Global Keratoconjunctivitis Market Size & Forecast (2022-2032)
- 1.2. Regional Summary
- 1.3. Segmental Summary
- 1.3.1. By Drug Class
- 1.3.2. By Route of Administration
- 1.3.3. By End-Users
- 1.3.4. By Distribution Channel
- 1.4. Key Trends
- 1.5. Recession Impact
- 1.6. Analyst Recommendation & Conclusion
Chapter 2. Global Keratoconjunctivitis Market Definition and Research Assumptions
- 2.1. Research Objective
- 2.2. Market Definition
- 2.3. Research Assumptions
- 2.3.1. Inclusion & Exclusion
- 2.3.2. Limitations
- 2.3.3. Supply Side Analysis
- 2.3.3.1. Availability
- 2.3.3.2. Infrastructure
- 2.3.3.3. Regulatory Environment
- 2.3.3.4. Market Competition
- 2.3.3.5. Economic Viability (Consumer's Perspective)
- 2.3.4. Demand Side Analysis
- 2.3.4.1. Regulatory Frameworks
- 2.3.4.2. Technological Advancements
- 2.3.4.3. Environmental Considerations
- 2.3.4.4. Consumer Awareness & Acceptance
- 2.4. Estimation Methodology
- 2.5. Years Considered for the Study
- 2.6. Currency Conversion Rates
Chapter 3. Global Keratoconjunctivitis Market Dynamics
- 3.1. Market Drivers
- 3.1.1. Rise in Allergies and Environmental Factors
- 3.1.2. Advancements in Biotechnology
- 3.2. Market Challenges
- 3.2.1. Side Effects and Resistance
- 3.2.2. Lack of Technical Skills
- 3.3. Market Opportunities
- 3.3.1. Increasing Demand for Retail Pharmacies
- 3.3.2. Increased Awareness and Education
Chapter 4. Global Keratoconjunctivitis Market Industry Analysis
- 4.1. Porter's 5 Force Model
- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.1.6. Futuristic Approach to Porter's 5 Force Model
- 4.1.7. Porter's 5 Force Impact Analysis
- 4.2. PESTEL Analysis
- 4.2.1. Political
- 4.2.2. Economic
- 4.2.3. Social
- 4.2.4. Technological
- 4.2.5. Environmental
- 4.2.6. Legal
- 4.3. Top Investment Opportunity
- 4.4. Top Winning Strategies
- 4.5. Disruptive Trends
- 4.6. Industry Expert Perspective
- 4.7. Analyst Recommendation & Conclusion
Chapter 5. Global Keratoconjunctivitis Market Size & Forecasts by Drug Class 2022-2032
- 5.1. Segment Dashboard
- 5.2. Global Keratoconjunctivitis Market: Drug Class Revenue Trend Analysis, 2022 & 2032 (USD Million)
- 5.2.1. NSAIDS
- 5.2.2. Corticosteroids
- 5.2.3. Antibiotics
- 5.2.4. Antivirals
- 5.2.5. Others
Chapter 6. Global Keratoconjunctivitis Market Size & Forecasts by Route of Administration 2022-2032
- 6.1. Segment Dashboard
- 6.2. Global Keratoconjunctivitis Market: Route of Administration Revenue Trend Analysis, 2022 & 2032 (USD Million)
- 6.2.1. Oral
- 6.2.2. Topical
- 6.2.3. Others
Chapter 7. Global Keratoconjunctivitis Market Size & Forecasts by End-Users 2022-2032
- 7.1. Segment Dashboard
- 7.2. Global Keratoconjunctivitis Market: End-Users Revenue Trend Analysis, 2022 & 2032 (USD Million)
- 7.2.1. Hospitals
- 7.2.2. Specialty Clinics
- 7.2.3. Homecare
- 7.2.4. Others
Chapter 8. Global Keratoconjunctivitis Market Size & Forecasts by Distribution Channel 2022-2032
- 8.1. Segment Dashboard
- 8.2. Global Keratoconjunctivitis Market: Distribution Channel Revenue Trend Analysis, 2022 & 2032 (USD Million)
- 8.2.1. Hospital Pharmacy
- 8.2.2. Retail Pharmacy
- 8.2.3. Online Pharmacy
- 8.2.4. Others
Chapter 9. Global Keratoconjunctivitis Market Size & Forecasts by Region 2022-2032
- 9.1. North America Keratoconjunctivitis Market
- 9.1.1. U.S. Keratoconjunctivitis Market
- 9.1.1.1. Drug Class breakdown size & forecasts, 2022-2032 (USD Million)
- 9.1.1.2. Route of Administration breakdown size & forecasts, 2022-2032 (USD Million)
- 9.1.1.3. End-Users breakdown size & forecasts, 2022-2032 (USD Million)
- 9.1.1.4. Distribution Channel breakdown size & forecasts, 2022-2032 (USD Million)
- 9.1.2. Canada Keratoconjunctivitis Market
- 9.1.3. Mexico Keratoconjunctivitis Market
- 9.1.4. Rest of North America Keratoconjunctivitis Market
- 9.1.1. U.S. Keratoconjunctivitis Market
- 9.2. Europe Keratoconjunctivitis Market
- 9.2.1. U.K. Keratoconjunctivitis Market
- 9.2.2. Germany Keratoconjunctivitis Market
- 9.2.3. France Keratoconjunctivitis Market
- 9.2.4. Spain Keratoconjunctivitis Market
- 9.2.5. Italy Keratoconjunctivitis Market
- 9.2.6. Rest of Europe Keratoconjunctivitis Market
- 9.3. Asia-Pacific Keratoconjunctivitis Market
- 9.3.1. China Keratoconjunctivitis Market
- 9.3.2. India Keratoconjunctivitis Market
- 9.3.3. Japan Keratoconjunctivitis Market
- 9.3.4. Australia Keratoconjunctivitis Market
- 9.3.5. South Korea Keratoconjunctivitis Market
- 9.3.6. Rest of Asia-Pacific Keratoconjunctivitis Market
- 9.4. Latin America Keratoconjunctivitis Market
- 9.4.1. Brazil Keratoconjunctivitis Market
- 9.4.2. Mexico Keratoconjunctivitis Market
- 9.4.3. Argentina Keratoconjunctivitis Market
- 9.4.4. Rest of Latin America Keratoconjunctivitis Market
- 9.5. Middle East & Africa Keratoconjunctivitis Market
- 9.5.1. Saudi Arabia Keratoconjunctivitis Market
- 9.5.2. South Africa Keratoconjunctivitis Market
- 9.5.4. Rest of Middle East & Africa Keratoconjunctivitis Market
Chapter 10. Competitive Intelligence
- 10.1. Key Company SWOT Analysis
- 10.2. Top Market Strategies
- 10.3. Company Profiles
- 10.3.1. Bausch Health Companies Inc.
- 10.3.1.1. Key Information
- 10.3.1.2. Overview
- 10.3.1.3. Financial (Subject to Data Availability)
- 10.3.1.4. Product Summary
- 10.3.1.5. Market Strategies
- 10.3.2. Merck & Co. Inc.
- 10.3.3. Pfizer Inc.
- 10.3.4. Teva Pharmaceutical Industries Ltd.
- 10.3.5. Amorphex Therapeutics Holdings, Inc.
- 10.3.6. Bayer AG
- 10.3.7. Novartis AG
- 10.3.8. Dr. Reddy's Laboratories Ltd
- 10.3.9. Endo International plc
- 10.3.10. Lupin
- 10.3.1. Bausch Health Companies Inc.
Chapter 11. Research Process
- 11.1. Research Process
- 11.1.1. Data Mining
- 11.1.2. Analysis
- 11.1.3. Market Estimation
- 11.1.4. Validation
- 11.1.5. Publishing
- 11.2. Research Attributes
